| 名称 | Onatasertib |
| 描述 | Onatasertib (CC223) is an orally available mTOR inhibitor with potential antitumor activity. Onatasertib inhibits the activity of mTOR, which may result in the induction of tumor cell apoptosis and a decrease in tumor cell proliferation. Onatasertib is a potent mTOR kinase inhibitor (IC50: 16 nM), with >150-fold sensitivity than the related lipid kinase PI3Kα (IC50: 4 μM). |
| 细胞实验 | Compound is spotted via an acoustic dispenser (EDC ATS-100) into an empty 384-well plate. Cells are diluted to desired densities and added directly to the compound-spotted plates. Cells are allowed to grow for 72 hours. Viability is assessed via Cell Titer-Glo. All data are normalized and represented as a percentage of the DMSO-treated cells. Results are then expressed as GI50 and/or IC50 values.(Only for Reference) |
| 激酶实验 | Kinase assays mTOR.: Reagents are prepared as follows:"Simple Tor buffer": 10 mM Tris pH 7.4, 100 mM NaCl, 0.1% Tween-20, 1 mM DTT. Recombinant mTOR is diluted in this buffer to an assay concentration of 0.200ug/mL. ATP/Substrate solution: 0.075 mM ATP, 12.5 mM MnCl2, 50 mM Hepes, pH 7.4, 50 mM β-GOP, 250 nM Microcystin LR, 0.25 mM EDTA, 5 mM DTT, and 3.5 μg/mL GST-p70S6. Dilution Curve: A 10-point, 1:3 dilution of compounds are prepared in neat DMSO at 50 times the final assay concentration. Detection reagent mix: 50 mM HEPES, pH 7.4 0.01% Triton X-100, 0.01% BSA, 0.1 mM EDTA, 12.7 ug/mL Cy5-anti-GST antibody, 9 ng/ml anti-phospho p70S6 antibody (Thr389), 627ng/mL anti-mouse IgG labeled with Lance Eu. To 20 uL of the Simple Tor buffer is added 0.5 uL of the compound Dilution Curve in DMSO. The final concentration range for compound is 30 to 0.0015 μM. To initiate the reaction, 5 μL of the ATP/substrate solution is added to the above. The reaction is allowed to run for 60 minutes. The assay is stopped by adding 5 μL of 60 mM EDTA. Ten (10) μL of detection reagent mix is then added, and the mixture is allowed to sit at least 2 hours before reading on a Perkin Elmer Envision microplate reader set to detect Europium-based TR-FRET. |
| 体外活性 | 在PC-3肿瘤移植的小鼠中,CC-223 (25 mg/kg,p.o.)抑制了mTORC1和mTORC2的活性.CC-223 (25 mg/kg, p.o.)还抑制了许多肿瘤模型的肿瘤生长,包括前列腺癌,神经胶质瘤,乳腺癌,肺癌以及结肠癌模型（47%-95%）. |
| 体内活性 | 在许多的细胞系中,CC-223对mTORC1 (S6RP and 4EBP1)和mTORC2 [AKT(S473)]标记物均有抑制作用,其IC50为pAKT（S473,11-150 nM）,pS6RP（27-184 nM）,p4EBP1（120-1050 nM）。CC-223还对许多癌细胞系的生长有抑制作用并诱导它们凋亡。 |
| 存储条件 | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. |
| 溶解度 | DMSO : 70 mg/mL (176.11 mM), Sonication is recommended.
Ethanol : 73 mg/mL (183.66 mM), Sonication is recommended.
H2O : < 1 mg/mL (insoluble or slightly soluble)
|
| 关键字 | PI3K-α | Onatasertib | mTOR | Mammalian target of Rapamycin | Inhibitor | inhibit | FLT4 | DNA-PK | DNAPK | c-Fms | cFms | ATG-008 | ATG008 | ATG 008 | Apoptosis |
| 相关产品 | L-Glutamic acid | Cysteamine hydrochloride | Alginic acid | Flubendazole | Dextran sulfate sodium salt (MW 5000) | 5-Fluorouracil | Stavudine | Tributyrin | Myricetin | L-Ascorbic acid sodium salt | L-Ascorbic acid | Sodium 4-phenylbutyrate |
| 相关库 | 抑制剂库 | 经典已知活性库 | 抗癌活性化合物库 | 已知活性化合物库 | 临床失败化合物库 | 抗衰老化合物库 | 高选择性抑制剂库 | 免疫/炎症分子化合物库 | 膜蛋白靶向化合物库 | 药物功能重定位化合物库 | 抗癌临床化合物库 | 抗癌药物库 |